CHARACTERIZATION AND RESPONSIVENESS OF MADISON 109 LUNG CARCINOMA TOO VARIOUS ANTI-TUMOR AGENTS

Google Scholar
  • 1 January 1977
    • journal article
    • research article
    • Vol. 61  (8) , 1459-1470
Abstract
The Madison 109 (M109) tumor was discovered in 1964 in the lung of a BALB/c mouse. This experimental carcinoma is maintained in vivo by s.c. passage in the right axillary region. When implanted i.m. (5 .times. 105 cells) into the right hind leg of BALB/c mice for testing, the primary tumor progresses with metastases to the lung, spleen, and liver. The metastases to the lung are visible within 3 wk and result in the death of the host in about 35 days after tumor implant. Implantation of a lung nodule is tumorigenic and lethal. Pyran polymer therapy delayed the appearance of lung metastases, inhibited the growth of the primary tumor and significantly increased the lifespan of BALB/c mice inoculated with M109 tumor. No spontaneous regression was observed and very few no takes occurred in untreated BALB/c mice inoculated with at least 500 M109 cells. Of the 82 agents tested so far, the M109 model has selected active agents such as actinomycin D, adriamycin, daunorubicin, DNA, procarbazine and pyran polymer. It showed no sensitivity as tested to several standard therapeutic agents including cytosine arabinoside, BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea], hydroxyurea, mechlorethamine, melphalan, triethylenemelamine, and vincristine.